MDR-TB
Introduction
Mycobacterium tuberculosis (MTB) is the most successful human pathogen worldwide causing an estimated 8.7 million new cases and more than 1.4 million deaths annually [1] . India has the highest estimated burden of tuberculosis (TB) in the world, accounting for 26% of all TB cases worldwide. The emergence of multidrug-resistant (MDR) strains of MTB 2212-5531/$ -see front matter Ó 2013 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights reserved. http://dx.doi.org/10.1016/j.ijmyco.2013. 10 .006 is threatening to make TB one of mankind's most pervasive infectious diseases incurable. These drug-resistant strains are more infectious by virtue of their high transmissibility in the population [2] . There are several genotypes of MTB.
MTB CAS1_Delhi lineage was first identified in Delhi region but now it is an emerging pathogen in several areas of the world, predominantly in South East Asian Countries. It belongs to the Spoligotype International Types (SIT) 26, 25, 141, 381, 1327, 1343 and 1344 CAS1_Delhi type (ST 26), and is highly prevalent in the Indian subcontinent [3, 4] . In Europe and Australia, these strains were often found to be associated with migrants from South Asia [5] . The lineage, however, is not considered to be more prone to resistance, as is the Beijing strain. When resistant, mutations in the rpoB, katG genes are more frequent in these isolates as compared with non-CAS_Delhi isolates [6] . It is also reported that an increasing frequency of drug resistance observed in the CAS1_Delhi sub-lineage isolates was not linked to the patients' history of previous anti-TB treatment [6] .
This study describes a unique case of four sequential isolations of MTB CAS1_Delhi genotype from a 22-year-old male patient from Delhi, India, and summarizes the data on their genotypes, drug resistance and possible evolution of MDR-TB from a sensitive strain of MTB. However, this patient did not follow the regimen, and he had several interruptions in the treatment, particularly after the intensive phase when his general condition improved and he became asymptomatic. Several sputum samples were collected during the follow-up period of treatment and subjected to BACTEC-MGIT-960 culture isolation. The base line culture was positive, and the isolate was identified as MTB by conventional phenotypic characteristics and confirmed by an in-house polymerase chain reaction (PCR) method [7] . This culture was labeled as isolate A. After three months of cessation of treatment (6 + 3 = 9 month, Fig. 1 ), his condition again deteriorated and his sputum sample was again positive for MTB. This second culture was labeled as isolate B. He was again prescribed with INH, RIF, PZA, EMB and streptomycin (STR). This regimen is known as category II as per the RNTCP, India guidelines. Within two months, his clinical condition again improved, but after a gap of four months, his symptoms reappeared. His sputum was again culture positive which was labeled as isolate C. The patient was once again prescribed with the same treatment for another 12 months, but this time also he stopped treatment after six months. After that, his condition further deteriorated and he died of disseminated disease. By this time 27 months had elapsed ( Fig. 1 ). Before his death, a fourth isolation was made from his sputum sample and labeled as isolate D.
Materials and methods

The patient and MTB isolates
All the four clinical isolates (A, B, C and D) were identified as MTB using standard protocols followed in our laboratory, which is accredited for culture, drug susceptibility and line probe assay [7, 8] and also by 16s RNA gene sequencing. The anti-mycobacterial drug susceptibility testing was performed on all the isolates by BACTEC-MGIT-960 (Becton Dickinson, Microbiology Systems, Sparks, MD), singly as well as in pairs. To determine the minimum inhibitory concentration (MIC), tetrazolium microplate assay (TEMA) and proportional method using Middlebrook 7H10 (Difco, Detroit, MI, USA) agar plates were used against first-line drugs. In proportional method the medium contained STR (2.0 lg/ml), INH (0.2 lg/ ml), RIF (1.0 lg/ml), and EMB (6.0 lg/ml) [7, 9, 10] .
From all cultures, DNA was extracted and subjected to spoligotyping using a commercial kit (Ocimum Biosolutions, India) as per the manufacturer's instructions [11] , and isolates were identified using the international SITVITWEB database [12, 13] . Further, 24-loci MIRU-VNTR was performed by PCR amplification of individual loci using specific primers as described previously [14] . The sequencing of 16sRNA for the rpoB, inhA, katG, embB, eis and rrs gene targets was done using the primers as described elsewhere [6, [15] [16] [17] [18] .
Results and discussion
Isolates, resistance pattern and gene mutations A 22-year-old male patient from Delhi was suspected of suffering from pulmonary TB (PTB) based on clinical history (cough, fever, chest pain, weight loss and loss of appetite), tuberculin skin test (16 mm) and chest X-ray done in AIIMS hospital. The chest X-ray showed bilateral cavitary lesions. The patient had a family history of contact with his brother who was a smear-positive case and who died of TB a few years ago. However, no isolation from his brother's samples was attempted, as it was not required to culture the samples under the national TB control program at that time. The initial result of Ziehl-Neelsen (ZN) staining of sputum was positive for acid-fast bacilli (AFB). Culture isolation and the drug susceptibility tests were performed using BACTEC-MGIT 960 (BD TM ), as per the World Health Organization (WHO) guidelines. The culture was identified as MTB by conventional phenotypic characteristics and confirmed by an in-house PCR method [8] . The patient was administered free anti-tubercular treatment (ATT) under the DOTS program of the Government of India. (Please see methods). Three more culture isolations were made during the course of the treatment period, albeit at irregular intervals, and these sequential isolates were la-beled as isolates A, B, C & D, respectively, as mentioned in the material and methods section (Fig. 1) .
The initial isolate (A) was sensitive to all of the four firstline drugs (STR, INH, RIF and EMB), but the consecutive isolates (isolates B, C and D) were found to be resistant to these drugs. The MIC of isolate B increased significantly to INH, RIF and EMB, however it was still sensitive to kanamycin. Significantly, the third and fourth isolates were found to be resistant not only to INH, RIF and EMB, but also to kanamycin (Fig. 1) . Infection with multiple strains or re-infection with other resistant strains during the course of treatment is common in endemic countries like India; hence, to confirm the clonal nature of all the four isolates, spoligotyping was done, and the results confirmed that all the isolates belonged to the family of Central Asian Strain Delhi (CAS1_Delhi, ST26) genotype in the SITVITWEB database. The 24-loci MIRU-VNTR patterns for all four isolates were identical and confirmed that all isolates belonged to the same family with identical MIRU-VNTR profiles (Fig. 1) . The sequencing of the rpoB (RIF r ), katG, inhA (INH r ), rrs and eis promoter regions (Kan r ) revealed mutated alleles associated with resistance to the INH, RIF, and EMB, but no mutation was found for kanamycin resistance, as shown in Fig. 1 . For INH resistance, katG 315 G-C, katG463 T-G and inhA-15 T-C were highly discernible between the baseline isolate and sequential isolates. Similarly, RIF resistance mutations were obvious in the second isolate (rpoB531C-T, but not for rpoB533T-C), but third and fourth isolates showed mutations in both alleles. To screen for EMB resistance associated mutations, ERDR region was also studied and embB294 (G-A) mutation in resistant isolates was found, i.e., second (B), third (C) and fourth (D) isolates, but not in baseline isolate (A).
The worldwide distribution of ST26 strains was essentially confined to the Middle East and Central Asia, more specifically in the Indian subcontinent (75%) [3, 4] . Hence as expected, the isolates also belonged to this most prevalent genotype.
There are only a few studies where differential MIC pattern and genetic mutations have been reported in drug-sensitive and drug-resistant isolates. Even these studies have been carried out on isolates obtained from different patients [19, 20] . Such isolates, therefore, do not provide deeper insight into the phenotypic and genotypic sequential events that occur in MTB under in vivo conditions. Only recently, Saunders et al. [21] reported a similar case in which they could isolate sequential isolates from a patient on anti-tubercular treatment, but their strategy of comparing sensitive and resistant isolates was different from the one used in this study. They only did deep sequencing of the isolates and found known mutations in katG and rpoB genes. Another study was published in 2012 from China [22] . In this study, the authors did whole genome sequencing of seven sequential isolates from three patients. The authors focused on the mixed diverse populations of MTB strains in clinical samples and on the selection of the most fit resistant strain in treatment failure cases. Even though the patient in this study did not show any mixed population at any stage, such instances are common but not frequently feasible to study. It is obvious from the case history of our patient that the mycobacteria remained under a constant intermittent drug pressure, which is considered to be the most suitable condition for selection of resistant strains in vivo [22] . However, the most interesting finding in this case is resistance selection for 4 drugs within 27 months. This is alarmingly the fastest selection process to best of this research's knowledge. The speed at which the strain turned from pan-sensitive to multidrug resistant is highly disturbing for TB control programs and indicates that more personalized counselling and awareness of strict adherence to the regular drug regimens cannot be compromised. This case also emphasizes the urgent need for compulsory isolations and forced treatment in such non-cooperative patients to contain the fast spread of MDR-TB.
